Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy

Abstract
No abstract available
Funding Information
  • National Cancer Institute (T32CA183926 – WJT, W81XWH-18-1-0231 - RCA)
  • U.S. Department of Defense (T32CA183926 – WJT, W81XWH-18-1-0231 - RCA)